Despite beating analysts' revenue and profit forecast, biotech's share price drops
(Newser) -
Drug maker Genentech – struggling with near-flat sales of its two premier drugs, Avastin and Rituxan – managed to outperform analyst’s fourth quarter expectations – barely, reports the Associated Press. The one-time biotech
uber star, which recorded phenomenal growth in each of the two previous years, showed only a...
More »
